Krsnaa Diagnost.

Has Krsnaa Diagnost. declared dividend?

Krsnaa Diagnostics Ltd has declared a 50% dividend, amounting to ₹2.5 per share, with an ex-date of September 13, 2024. The company's total returns have varied significantly across different periods, with recent performance showing a total return of -30.77% over the last 6 months and 22.43% over the past year.

Krsnaa Diagnostics Ltd has declared a 50% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 2.5<BR>- Ex-date: Sep-13-2024<BR><BR>Dividend Yield: 0.38%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Krsnaa Diagnostics experienced a price return of -30.77%, a dividend return of 0%, resulting in a total return of -30.77%.<BR><BR>Over the past year, the company saw a price return of 22.01% and a dividend return of 0.42%, leading to a total return of 22.43%.<BR><BR>In the 2-year period, the price return was 20.56%, with a dividend return of 0.90%, culminating in a total return of 21.46%.<BR><BR>For the 3-year period, Krsnaa Diagnostics had a price return of 21.22% and a dividend return of 1.52%, resulting in a total return of 22.74%.<BR><BR>In the 4-year period, the company recorded a price return of 0% and a dividend return of 0%, leading to a total return of 0.0%.<BR><BR>Over the last 5 years, Krsnaa Diagnostics experienced a price return of 0% and a dividend return of 0%, resulting in a total return of 0.0%.<BR><BR>Overall, Krsnaa Diagnostics has declared a dividend, but the total returns over various periods show significant variability, with some periods reflecting strong price returns while others indicate no dividend returns.

Who are the peers of the Krsnaa Diagnost.?

Krsnaa Diagnost.'s peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Tarsons Products, Suraksha Diagno., 3B Blackbio, and Sastasundar Ven. In terms of performance, 3B Blackbio leads with an 84.89% return, while Krsnaa Diagnost. has a 14.76% return, higher than Syngene Intl.'s -3.47%.

Peers: The peers of Krsnaa Diagnost. are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Tarsons Products, Suraksha Diagno., 3B Blackbio, and Sastasundar Ven.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, and Vijaya Diagnost., and the rest have Average or Below Average management risk. Growth ratings show that Excellent growth is seen at 3B Blackbio, Good growth at Suraksha Diagno., and Average growth at Poly Medicure, Indegene, and the rest, while Below Average growth is noted for Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Krsnaa Diagnost., and Tarsons Products. Excellent capital structure is present at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Krsnaa Diagnost., Sastasundar Ven., and the rest have Good or Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is 3B Blackbio at 84.89%, while the lowest is Syngene Intl. at -3.47%. Krsnaa Diagnost.'s 1-year return of 14.76% is higher than Syngene Intl. but lower than 3B Blackbio. Additionally, the peers with negative six-month returns include Syngene Intl., Poly Medicure, Vijaya Diagnost., Krsnaa Diagnost., Tarsons Products, and Sastasundar Ven.

Who are in the management team of Krsnaa Diagnost.?

As of March 2022, the management team of Krsnaa Diagnost includes Rajendra Mutha (Executive Chairman), Pallavi Bhatevara (Managing Director), Yash Mutha (Whole-Time Director), and several independent directors, including Chetan Desai and Chhaya Palrecha, among others. The team oversees the company's governance and operations.

As of March 2022, the management team of Krsnaa Diagnost consists of the following individuals:<BR><BR>1. Chetan Desai - Independent Director<BR>2. Rajendra Mutha - Executive Chairman & Whole-Time Director<BR>3. Pallavi Bhatevara - Managing Director<BR>4. Yash Mutha - Whole-Time Director<BR>5. Prem Pradeep - Nominee<BR>6. Chhaya Palrecha - Independent Director<BR>7. Rajiva Ranjan Verma - Independent Director<BR>8. Adesh Gupta - Independent Director<BR>9. Sujoy Sudipta Bose - Company Secretary & Compliance Officer<BR><BR>This team includes a mix of executive and independent directors, contributing to the governance and operational management of the company.

What does Krsnaa Diagnost. do?

Krsnaa Diagnostics Ltd is a healthcare services company specializing in diagnostic services, with a market cap of INR 2,642 Cr and reported net sales of 1,861 Cr and net profit of 207 Cr for March 2025. The company was founded in 2010 and became public in 2021.

Overview: <BR>Krsnaa Diagnostics Ltd is a healthcare services company operating in the small-cap market segment.<BR><BR>History: <BR>Krsnaa Diagnostics Limited was originally incorporated as Krsna Diagnostics Private Limited in 2010. The company underwent a name change to Krsnaa Diagnostics Private Limited in 2015 and later converted to a public company, adopting its current name in May 2021. The most recent quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 1,861 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 207 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 2,642 Cr (Small Cap) <BR><BR>Key Metrics: <BR>P/E: 35.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.30% <BR>Debt-Equity: 0.15 <BR>Return on Equity: 8.79% <BR>Price to Book: 3.00 <BR><BR>Contact Details: <BR>Address: S.No. 243/A Hissa No.6 Near, Chinchwad Station Chinchwad Pune Maharashtra : 411019 <BR>Tel: 91-20-46954695 <BR>Email: cs@krsnadiagnostics.com <BR>Website: http://www.krsnaadiagnostics.com

Who are the top shareholders of the Krsnaa Diagnost.?

The top shareholders of Krsnaa Diagnost include Rajendra Khivraj Mutha with 24.87%, Phi Capital Trust - Phi Capital Growth Fund - I at 15.44%, individual investors with 29.13%, mutual funds holding 9.36%, and foreign institutional investors at 3.55%.

The top shareholders of Krsnaa Diagnost include Rajendra Khivraj Mutha, who holds the highest promoter stake at 24.87%. The highest public shareholder is Phi Capital Trust - Phi Capital Growth Fund - I, with a holding of 15.44%. Additionally, individual investors collectively hold 29.13% of the shares. The company also has mutual funds holding 9.36% across four schemes and foreign institutional investors (FIIs) holding 3.55% through 47 different entities.

How big is Krsnaa Diagnost.?

As of 24th July, Krsnaa Diagnostics Ltd has a market capitalization of 2,786.00 Cr, with recent net sales of 717.16 Cr and a net profit of 77.62 Cr. The company reported shareholder's funds of 809.80 Cr and total assets of 1,170.28 Cr for the annual period ending March 2024.

As of 24th July, Krsnaa Diagnostics Ltd has a market capitalization of 2,786.00 Cr, classifying it as a Small Cap company.<BR><BR>In the latest four quarters, Krsnaa Diagnostics reported Net Sales of 717.16 Cr and a Net Profit of 77.62 Cr.<BR><BR>For the latest annual period ending March 2024, the company reported Shareholder's Funds of 809.80 Cr and Total Assets of 1,170.28 Cr.

Is Krsnaa Diagnost. overvalued or undervalued?

As of November 17, 2025, Krsnaa Diagnostics is fairly valued with a PE ratio of 31.76, lower than peers like Apollo Hospitals and Max Healthcare, and has outperformed the Sensex over the past three years with a return of 79.08%.

As of 17 November 2025, Krsnaa Diagnostics has moved from a very attractive to an attractive valuation grade. The company is currently considered fairly valued. Key ratios include a PE ratio of 31.76, an EV to EBITDA of 13.62, and a PEG ratio of 1.47. <BR><BR>In comparison to peers, Krsnaa Diagnostics has a lower PE ratio than Apollo Hospitals, which stands at 64.41, indicating that Krsnaa may be more reasonably priced despite its attractive valuation. Other peers like Max Healthcare and Fortis Healthcare are significantly more expensive, with PE ratios of 77.22 and 70.78, respectively. Although Krsnaa Diagnostics has underperformed the Sensex year-to-date, it has shown strong returns over the past three years, outperforming the index with a return of 79.08%.

How has been the historical performance of Krsnaa Diagnost.?

Krsnaa Diagnost. has shown consistent growth in net sales and profitability over the past four years, with net sales increasing from 455.45 Cr in Mar'22 to 717.16 Cr in Mar'25, and profit after tax rising from 68.39 Cr to 77.61 Cr in the same period. The company also improved its operating profit margin and cash flow from operating activities significantly.

Answer:<BR>The historical performance of Krsnaa Diagnost. shows a consistent growth trend in net sales and profitability over the past four years.<BR><BR>Breakdown:<BR>Krsnaa Diagnost. has demonstrated a steady increase in net sales, rising from 455.45 Cr in Mar'22 to 717.16 Cr in Mar'25. Total operating income followed a similar trajectory, reaching 717.16 Cr in Mar'25, up from 455.45 Cr in Mar'22. The company's total expenditure also increased, from 323.97 Cr in Mar'22 to 527.04 Cr in Mar'25, driven by higher raw material and employee costs. Operating profit (PBDIT) grew significantly, from 146.39 Cr in Mar'22 to 215.66 Cr in Mar'25, reflecting an improved operating profit margin of 26.51% in Mar'25 compared to 28.87% in Mar'22. Profit before tax increased from 86.51 Cr in Mar'22 to 102.69 Cr in Mar'25, while profit after tax rose from 68.39 Cr to 77.61 Cr in the same period. The company's total assets increased from 875.37 Cr in Mar'22 to 1,278.26 Cr in Mar'25, with total liabilities also rising from 875.37 Cr to 1,278.26 Cr. Cash flow from operating activities improved to 87.00 Cr in Mar'25, up from 24.00 Cr in Mar'24, indicating a positive cash flow trend. Overall, Krsnaa Diagnost. has shown robust growth in sales, profits, and asset base over the years.

Is Krsnaa Diagnost. technically bullish or bearish?

As of December 3, 2025, Krsnaa Diagnostics shows a mildly bearish trend due to bearish MACD readings and Bollinger Bands, despite a mildly bullish daily moving average, and has underperformed compared to the Sensex.

As of 3 December 2025, the technical trend for Krsnaa Diagnostics has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by weekly and monthly MACD readings indicating a bearish trend, along with Bollinger Bands and KST also reflecting bearish signals. The moving averages on the daily timeframe show a mildly bullish stance, but this is overshadowed by the overall bearish indicators on the weekly and monthly timeframes. The stock has underperformed significantly compared to the Sensex over various periods, further supporting the bearish outlook.

When is the next results date for Krsnaa Diagnostics Ltd?

The next results date for Krsnaa Diagnostics Ltd is February 5, 2026.

The next results date for Krsnaa Diagnostics Ltd is scheduled for February 5, 2026.

Are Krsnaa Diagnostics Ltd latest results good or bad?

Krsnaa Diagnostics Ltd's latest results are concerning, showing a 27.9% decline in net profit and compressed operating margins, leading to a downgrade in their Mojo Score and a "STRONG SELL" rating. Despite consistent revenue growth, the deterioration in profitability raises questions about the company's financial stability.

Krsnaa Diagnostics Ltd's latest results indicate a concerning trend. In the most recent quarter (Q3 FY26), the company experienced a dramatic 27.9% decline in net profit, dropping to ₹15.25 crores. This marks a significant shift from previous positive financial performance. Additionally, operating margins have compressed to 26.63% from 28.72% in the prior quarter, and interest costs surged by 21.89% on a half-yearly basis, raising concerns about the company's operational efficiency and financial stability.<BR><BR>While the company has shown consistent revenue growth, achieving a 15.8% annual increase in FY25, the deterioration in profitability metrics raises questions about the sustainability of this growth amidst rising costs. The overall financial trend has shifted from positive to negative, leading to a downgrade in the company's Mojo Score to 28/100, with a "STRONG SELL" rating.<BR><BR>In summary, the latest results are viewed as bad, highlighting significant operational challenges and financial stress.

Should I buy, sell or hold Krsnaa Diagnostics Ltd?

Which are the latest news on Krsnaa Diagnost.?

Why is Krsnaa Diagnostics Ltd falling/rising?

As of 10-May, Krsnaa Diagnostics Ltd's stock price is at 600.95, reflecting a decline of 0.67%. The stock has underperformed significantly, with a 14.88% loss over the past year and reduced investor interest, indicated by a 26.07% drop in delivery volume.

As of 10-May, Krsnaa Diagnostics Ltd's stock price is falling, currently at 600.95, which reflects a decrease of 4.05 or 0.67%. The stock has been underperforming, having lost 1.97% over the last two days and showing a performance today that is 2.94% lower than its sector. Additionally, the stock has generated a return of -14.88% over the past year, which indicates a below-par performance in the long term as well.<BR><BR>Investor participation has also declined, with a significant drop in delivery volume by 26.07% compared to the 5-day average, suggesting reduced interest in trading the stock. Despite touching an intraday high of Rs 622 earlier in the day, the overall trend remains negative, as the stock is trading below its 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish sentiment among investors.<BR><BR>Moreover, the company's recent financial results have contributed to the negative outlook. The profit after tax for the latest quarter has fallen by 27.9% compared to the previous four-quarter average, and while profits have increased by 6.3% over the past year, the stock's performance has not reflected this growth positively. The debt to equity ratio is low at 0.09, which is generally favorable, but the overall financial metrics, including a low operating profit to interest ratio, suggest challenges ahead.<BR><BR>In summary, the combination of recent poor financial results, declining investor participation, and overall underperformance compared to benchmarks has led to the stock's current downward trend.